Clinical outcomes of WHO 2022 and ICC MDS entities with risk stratification by IPSS-R and IPSS-M

Ítems similars

• Clinical outcomes of WHO 2022 and ICC MDS entities with risk stratification by IPSS-R and IPSS-M
  per: Daehun Kwag, et al.
  Publicat: (2025-10-01)
• IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation
  per: Huixian Wu, et al.
  Publicat: (2025-07-01)
• Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification
  per: Wan-Hsuan Lee, et al.
  Publicat: (2026-03-01)
• Improving MDS Risk Assessment: The Role of Monocytopenia and Lymphocytopenia Beyond IPSS-R
  per: Marijana Virijevic, et al.
  Publicat: (2025-09-01)
• Validation and comparison of the molecular international prognostic scoring system (IPSS-M) and the revised international prognostic scoring system (IPSS-R) in myelodysplastic neoplasms (MDS): a retrospective study
  per: Mengmeng Hu, et al.
  Publicat: (2025-12-01)